These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22096965)

  • 21. Peginterferon and lamivudine for hepatitis B.
    Assy NN; Hussein O
    N Engl J Med; 2004 Dec; 351(27):2879; author reply 2879. PubMed ID: 15625344
    [No Abstract]   [Full Text] [Related]  

  • 22. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
    Kaymakoglu S; Oguz D; Gur G; Gurel S; Tankurt E; Ersöz G; Ozenirler S; Kalayci C; Poturoglu S; Cakaloglu Y; Okten A
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3020-2. PubMed ID: 17517832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [High dose of pegylated interferon alpha-2a for the treatment of genotype1 chronic hepatitis C: a case report].
    Wu CH; Wang LF; Xu XY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):873. PubMed ID: 21138646
    [No Abstract]   [Full Text] [Related]  

  • 24. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
    Chan HL; Wong GL; Chim AM; Chan HY; Chu SH; Wong VW
    Antivir Ther; 2011; 16(8):1249-57. PubMed ID: 22155906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical analysis of seroconversion of HBsAg in chronic hepatitis B patients treated with PegIFN alpha-2a].
    Yang F; Wu XF; Li XH; Wei N
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):950-1. PubMed ID: 20038343
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
    Marcellin P
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 2():S99-102. PubMed ID: 21095519
    [No Abstract]   [Full Text] [Related]  

  • 27. The maze of treatments for hepatitis B.
    Lok AS
    N Engl J Med; 2005 Jun; 352(26):2743-6. PubMed ID: 15987924
    [No Abstract]   [Full Text] [Related]  

  • 28. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG; Lau DT; Schmid P; Perrillo R
    Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Looking to the future: new agents for chronic hepatitis B.
    Dienstag JL
    Am J Gastroenterol; 2006; 101 Suppl 1():S19-25. PubMed ID: 16448448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of chronic hepatitis B].
    Lengyel G; Fehér J
    Orv Hetil; 2004 Sep; 145(36):1861-3. PubMed ID: 15508405
    [No Abstract]   [Full Text] [Related]  

  • 31. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
    Chen XF; Chen XP; Ma XJ; Chen WL; Luo XD; Liao JY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):502-5. PubMed ID: 24074707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment options in chronic hepatitis B].
    Nitschmann S
    Internist (Berl); 2006 Mar; 47(3):308-9; discussion 309-10. PubMed ID: 16485097
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
    Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
    Maticic M; Luznik Z; Stepec S; Popovic P; Snedec N; Poljak M; Stanisavljevic D
    J Clin Gastroenterol; 2014; 48(5):464-5. PubMed ID: 24275712
    [No Abstract]   [Full Text] [Related]  

  • 35. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    Janssen HL; Sonneveld MJ; Brunetto MR
    Gut; 2012 May; 61(5):641-5. PubMed ID: 22180061
    [No Abstract]   [Full Text] [Related]  

  • 36. [Management of chronic hepatitis B].
    von Weizsäcker F
    Praxis (Bern 1994); 2005 Apr; 94(16):649-52. PubMed ID: 15900829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
    Huang Z; Zhao Z; Zheng Y; Peng L; Lin C; Deng H; Gao Z
    J Viral Hepat; 2013 Apr; 20 Suppl 1():52-7. PubMed ID: 23458525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Applicability of cost-effectiveness analysis to management of chronic hepatitis B.
    Dan YY; Lim SG
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1357-9. PubMed ID: 17716341
    [No Abstract]   [Full Text] [Related]  

  • 39. The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy.
    Lampertico P
    Hepatology; 2015 May; 61(5):1459-61. PubMed ID: 25645624
    [No Abstract]   [Full Text] [Related]  

  • 40. Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge.
    Coton T; Diallo I
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):e95. PubMed ID: 23663919
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.